Housing Watch Web Search

Search results

1. Results From The WOW.Com Content Network

2. Age-Related Eye Disease Study - Wikipedia

   en.wikipedia.org/wiki/Age-Related_Eye_Disease_Study

   The Age-Related Eye Disease Study ( AREDS) was a clinical trial sponsored by the National Eye Institute that ran from 1992 to 2001. [1] The study was designed to: investigate the natural history and risk factors of age-related macular degeneration (AMD) and cataracts, and. evaluate the effects of high doses of antioxidants and zinc on the ...

3. Macular degeneration - Wikipedia

   en.wikipedia.org/wiki/Macular_degeneration

   8.7% global prevalence in 2020 [2] Macular degeneration, also known as age-related macular degeneration ( AMD or ARMD ), is a medical condition which may result in blurred or no vision in the center of the visual field. [1] Early on there are often no symptoms. [1] Over time, however, some people experience a gradual worsening of vision that ...

4. List of adverse effects of risperidone - Wikipedia

   en.wikipedia.org/wiki/List_of_adverse_effects_of...

   This is a list of adverse effects of risperidone. Risperidone , sold under the brand name Risperdal among others, is an antipsychotic . [1] It is used to treat schizophrenia , bipolar disorder , and irritability associated with autism .

5. These Common Medications May Put You at Greater Risk for a ...

   www.aol.com/common-medications-may-put-greater...

   ACE inhibitors. ACE inhibitors are used to treat and manage high blood pressure, which is a big risk factor for heart disease, heart failure, stroke, and more. ACE inhibitors can lower your thirst ...

6. Weight-loss options for US youth are hard to come by - AOL

   www.aol.com/news/weight-loss-options-us-youth...

   Novo Nordisk's Wegovy was approved for adults in 2021 and for adolescents in late 2022, offering a highly effective way to lose weight for the first time. Novo still cannot meet demand for the ...

7. Moxonidine - Wikipedia

   en.wikipedia.org/wiki/Moxonidine

   Moxonidine. Moxonidine ( INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.